Searched over 200M research papers
10 papers analyzed
These studies suggest that medications like acetylcholinesterase inhibitors, dopamine agonists, and selective serotonin reuptake inhibitors can cause insomnia.
20 papers analyzed
Insomnia, characterized by difficulty in falling asleep, staying asleep, or experiencing non-refreshing sleep, can be exacerbated by various medications. Understanding which medications contribute to sleep disturbances is crucial for managing and mitigating insomnia.
SSRIs, commonly prescribed for depression and anxiety, are frequently associated with sleep disturbances. Studies have shown that SSRIs like paroxetine can improve subjective sleep measures in some cases, but the overall evidence is mixed and often of low quality. Additionally, SSRIs are among the drug classes most significantly associated with sleep disturbances.
TCAs, such as doxepin and trimipramine, have shown moderate improvements in sleep quality over placebo. However, their impact on sleep latency is minimal, and they may cause adverse effects like morning grogginess and dry mouth. Despite their potential benefits, the safety and tolerability of TCAs for insomnia remain uncertain due to limited reporting of adverse events.
Trazodone, another antidepressant, has been found to moderately improve subjective sleep outcomes but also comes with side effects such as morning grogginess and increased dry mouth. Mianserin, although less commonly used, has shown some effectiveness in treating insomnia related to opiate withdrawal.
Benzodiazepines, such as nitrazepam and midazolam, are effective in inducing sleep but are no longer recommended as first-line treatments due to their potential for dependence, tolerance, and rebound insomnia. They are particularly discouraged in older adults due to risks of cognitive impairment, falls, and accidents.
Non-BzRAs like zolpidem and eszopiclone are preferred over benzodiazepines due to a better safety profile. However, they still pose risks such as dementia, serious injury, and fractures, especially in the elderly. Zolpidem has shown effectiveness in both sleep induction and maintenance, but its use should be limited to avoid long-term side effects.
These medications, often used for conditions like Alzheimer's disease and Parkinson's disease, are significantly associated with sleep disturbances. Their impact on sleep can exacerbate insomnia symptoms, making it essential to monitor patients closely.
Second-generation antipsychotics, such as quetiapine and olanzapine, are increasingly used off-label for insomnia despite limited evidence of their efficacy. These drugs may improve sleep while treating comorbid conditions but come with a different side effect profile compared to traditional hypnotics.
Sedating antihistamines like diphenhydramine are commonly used for their sleep-inducing properties. However, they are not recommended for older adults due to the risk of residual sedation and cognitive impairment.
Several medications, including SSRIs, TCAs, benzodiazepines, non-BzRAs, acetylcholinesterase inhibitors, dopamine agonists, antipsychotics, and antihistamines, can contribute to insomnia. While some of these drugs may improve sleep in the short term, their long-term use is often associated with significant side effects and risks. Clinicians should carefully consider these factors when prescribing medications to patients with insomnia and explore non-pharmacologic treatments as first-line options.
Most relevant research papers on this topic
94 Citations